Immune Response BioPharma Values Company & Pipeline Between $1-5 Billion Conservatively Led by Lead Products NeuroVax, Remune, RemuneX & Sepsicillin, First in Class Treatments for AIDS, MS and Sepsis. IRBP Sees Remune Pricing around $500 per Dose and RemuneX around $750 per Dose.
Immune Response BioPharma, Fredericksburg, Virginia Today 6/02/2011 privately held, announces it values its proprietary pipeline of vaccines and-drugs in the AIDS, MS, and Sepsis areas of autoimmune and infectious disease areas conservatively between $1-5 Billion dollars led by lead products NeuroVax, Remune, RemuneX and Sepsicillin all first in class and best in class treatments for the diseases of HIV, Multiple Sclerosis, and Sepsis Shock.
IRBP’s pipeline is second to none in the biotech and pharmaceutical-industries. With close to 41 million patients diagnosed with HIV or full blown AIDS a Vaccine such as Remune and RemuneX at $500 and $750 per dose it doesn’t take long to reach a fair valuation for the company and its proprietary pipeline. RemuneX will be slightly higher in price as it contains an adjuvant which increases its strength. IRBP’s goal is to bring innovative drugs and vaccines to patients across a wide scope of diseases at the lowest cost with the most effective treatment options available today.
“IRBP will get the price of Remune and RemuneX as low as it can if we can to help defeat this wicked virus and I will be reaching out to big pharma to handle the manufacturing and partnering of Remune & RemuneX and seek a commercial venture for the vaccines. This is a highly complex manufacturing process you just can’t start ramping up a vaccine like Remune without special handling and care. Partial immunity is better than no immunity, saving lives is paramount to our mission” IRBP COO Mr. Buswell.
Immune Response BioPharma is a diversified biopharmaceutical company engaged in the process of developing lifesaving drugs and therapeutic vaccines in the auto-immune, infectious disease areas. The company has a deep pipeline of experimental drugs it plans to develop. Plans to raise capital is neither an offer nor solicitation for sale of securities. Forward looking statements are based upon future projections, timeframes and current information and IRBP makes no guarantee that its products will be successful or approved in a highly regulated market. Clinical trials and data may not be sufficient to satisfy regulatory requirements. Safe Harbor disclosure. Immune Response BioPharma may be found on the world wide web at www.immuneresponsebiopharma.com
